Physician profile
Michael D Raida
NPI 1518910389
$8,947.52
in general payments reported to CMS, 2019-2025
27 companies · $1,477 in 2025
The $1,477 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,679 · 2020: $442 · 2021: $414 · 2022: $1,204 · 2023: $1,736 · 2024: $1,995 · 2025: $1,477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,207.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,196.23 | 2022-2025 | Caplyta |
| Abbvie INC. | $1,142.13 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,075.63 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $906.57 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $809.26 | 2019-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $693.61 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $535.75 | 2019-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $382.01 | 2023-2025 | Qelbree, Qelbree |
| Almatica Pharma LLC | $356.12 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Axsome Therapeutics, INC. | $328.62 | 2022-2025 | Auvelity |
| Allergan, INC. | $255.27 | 2019-2020 | |
| Bausch Health US, LLC | $200.59 | 2019-2025 | Aplenzin, Wellbutrin |
| Teva Pharmaceuticals USA, INC. | $174.30 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $143.84 | 2024-2025 | Fanapt |
| Corium, LLC | $141.48 | 2022-2025 | Azstarys |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $118.79 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $111.87 | 2024-2025 | Cobenfy |
| Shire North American Group INC | $79.94 | 2019 | |
| Alkermes, INC. | $56.49 | 2023-2025 | Lybalvi |
| Biogen, INC. | $47.16 | 2024 | Zurzuvae |
| Noven Therapeutics, LLC | $38.73 | 2023 | Xelstrym, Secuado |
| Ironshore Pharmaceuticals INC. | $38.38 | 2019 | |
| Alfasigma USA, INC. | $38.00 | 2022 | |
| Eisai INC. | $22.64 | 2021 | |
| Tris Pharma INC | $20.67 | 2023 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $19.48 | 2023 | Quviviq |
| Avanir Pharmaceuticals, INC. | $13.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Raida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.